Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors

Future Med Chem. 2020 Jan;12(1):51-68. doi: 10.4155/fmc-2019-0158. Epub 2019 Nov 15.

Abstract

Aim: Antibiotic resistance is an alarming issue, as multidrug-resistant bacteria are growing worldwide, hence the decrease of therapeutic potential of available antibiotic arsenal. Among these bacteria, Staphylococcus aureus was pointed by the WHO in the pathogens list to be prioritized in drug development. Methods: We report the use of chemical similarity models for the virtual screening of new antibacterial with structural similarity to known inhibitors of FabI. The potential inhibitors were experimentally evaluated for antibacterial activity and membrane disrupting capabilities. Results & conclusion: These models led to the finding of four new compounds with antibacterial activity, one of which having antimicrobial activity already reported in the literature.

Keywords: FabI inhibitors; MRSA; Staphylococcus aureus; antibacterial; ligand-based virtual screening; similarity search.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology*
  • Drug Evaluation, Preclinical
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / antagonists & inhibitors*
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / metabolism
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Microbial Sensitivity Tests
  • Models, Molecular
  • Molecular Structure
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / metabolism

Substances

  • Anti-Bacterial Agents
  • Enzyme Inhibitors
  • Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)